Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: Johnson & Johnson | Contract Pharma

What are you searching for?

Sign in
Financial News

Financial Report: Johnson & Johnson

Revenues up 2% in the quarter

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Johnson & Johnson

1Q Revenues: $17.8 billion (+2%)

1Q Earnings: $4.4 billion (-1%)

Comments: Domestic sales increased 0.6%. International sales increased 2.8%, reflecting operational growth of 3.6% and a negative currency impact of 0.8%. Worldwide Pharmaceutical sales were $8.2 billion, up 1%. REMICADE sales were down 6% to $1.7 billion, offset by growth drivers in new products including DARZALEX, with sales of $255 million. IMBRUVICA sales were $409 million, up 57%. STELARA sales were $823 million, up 12%. INVEGA SUSTENNA/XEPLION/TRINZA sales were up 18% to $604 million. During the quarter, the company announced a definitive agreement to acquire Actelion Ltd., a biopharmaceutical company, for approximately $30 billion.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters